ALung Technologies Reports FDA Granted the Company Emergency Use Authorization Designation to the Hemolung® Respiratory Assist System for RX of COVID-19

ALung Technologies announced that the Food and Drug Administration (FDA) has granted the Company Emergency Use Authorization (EUA) designation to the Hemolung® Respiratory Assist System (RAS) for the treatment of Coronavirus Disease 2019 (COVID-19) patients.

ALung Technologies has treated numerous COVID-19 patients in the U.S. under existing FDA Emergency Use Provisions, and in the European Union, where the Company is approved having been granted their CE Mark in 2013.

The Hemolung® RAS is currently being used in the FDA approved VENT-AVOID trial for the study of ECCO2R in the treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AE-COPD). In addition, the Hemolung RAS and ECCO2R have been studied for the treatment of moderate to severe Acute Respiratory Distress Syndrome (ARDS) in the just concluded UK REST trial, which enrolled 412 patients.

A public health emergency related to COVID-19 was declared by the Secretary of Health and Human Services (HHS) on February 4, 2020. The FDA has issued a EUA for the Hemolung RAS to treat lung failure caused by COVID-19. As indicated in the FDA’s EUA letter to ALung, the Hemolung RAS is not FDA-cleared or approved, and there are no FDA-approved or cleared device treatments for lung failure caused by COVID-19. ALung submitted and the FDA reviewed in vitro and in vivo information in support of ALung’s ongoing U.S. VENT-AVOID clinical trial for the Hemolung RAS as well as additional information about the clinical use of the Hemolung RAS outside the U.S., and additional biocompatibility, cytotoxicity, and performance testing.

Based on the information submitted, the FDA stated that it believes the Hemolung RAS has the potential to treat lung failure as an adjunct to noninvasive or invasive mechanical ventilation, to reduce hypercapnia and hypercapnic acidosis due to COVID-19, and/or to maintain normalized levels of partial pressure of carbon dioxide(PCO2) and pH in patients suffering from acute, reversible respiratory failure due to COVID-19 for whom ventilation of CO2 cannot be adequately, safely, or tolerably achieved and, in turn, may provide clinical benefit, and that there is no adequate, approved and available alternative to the emergency use of the Hemolung RAS to treat lung failure caused by COVID-19.

“We are pleased with the FDA’s recognition that the Hemolung may be beneficial in the treatment of COVID-19 by removal of CO2 directly from the blood during extracorporeal therapy,” said Mr. Peter M. DeComo, Chairman and CEO of ALung Technologies.

Mr. DeComo further stated, “With published mortality rates as high as 90% for patients receiving invasive mechanical ventilation (IMV), we believe that the Hemolung can be a valuable tool for physicians to be used in conjunction with IMV, by reducing or eliminating the potential of further lung damage caused by high ventilator driving pressures, often referred to as Ventilator Induced Lung Injury (VILI). Many of the academic medical centers involved with our clinical trial have already requested the use of the Hemolung RAS for treatment of their COVID-19 patients.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy